Intranasal vaccination against influenza using pharmaceutical excipients as immunological adjuvants

S. Gizurarson*, H. Aggerbeck, S. Gudny Arnadottir, C. H. Mordhorst, I. Heron

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Secretory antibodies in mucosal surfaces are known to play an essential sole in protection against various infectious diseases such as influenza. To enhance the production of such antibodies, split influenza virus vaccine was inoculated intranasally into mice and rabbits together with some pharmaceutical excipients. The excipients were chosen among several possible substances in order to evaluate their ability to act as immunological adjuvants. A combination of polysorbate 20 and caprylic/capric glyceride resulted in high levels of serum immunoglobulin G (IgG) and nasal IgA responses against influenza virus, 5 weeks after immunization. Various factors were studied, such as the effect of the concentration of each individual excipient, the effect of total adjuvant concentration, and the influence of influenza virus concentration. The mechanisms for these adjuvants are not known, but the results show that they prove to be effective in inducing IgG and sIgA antibodies against influenza virus, and therefore are more likely to stimulate an immune response where it is most needed, compared with the conventional subcutaneous vaccines.

Original languageEnglish
Pages (from-to)69-75
Number of pages7
JournalVaccine Research
Issue number2
Publication statusPublished - 1996


Dive into the research topics of 'Intranasal vaccination against influenza using pharmaceutical excipients as immunological adjuvants'. Together they form a unique fingerprint.

Cite this